drugset / Trial / NCT01554917

A Study of Iguratimod in Patients With Active Rheumatoid Arthritis

NCT01554917

Phase 4 Completed 1759 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is intended to evaluate the safety and efficacy of Iguratimod in patients with active Rheumatoid Arthritis.

Timeline

Start
2012-05
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Iguratimod Small molecule 25 mg Oral

Indications